GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Shares Buyback Ratio %

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Shares Buyback Ratio % : 0.00 (As of May. 15, 2024)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. IntelliPharmaCeutics International's current shares buyback ratio was 0.00%.


IntelliPharmaCeutics International Shares Buyback Ratio % Historical Data

The historical data trend for IntelliPharmaCeutics International's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Shares Buyback Ratio % Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -425.93 -21.00 -7.21 -39.76 -

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IntelliPharmaCeutics International Shares Buyback Ratio % Calculation

IntelliPharmaCeutics International's Shares Buyback Ratio for the fiscal year that ended in Nov. 2022 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Nov. 2021 ) - Shares Outstanding (EOP) (A: Nov. 2022 )) / Shares Outstanding (EOP) (A: Nov. 2021 )
=(33.0927 - 33.0927) / 33.0927
=0.00%

IntelliPharmaCeutics International's Shares Buyback Ratio for the quarter that ended in Aug. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: May. 2023 ) - Shares Outstanding (EOP) (A: Aug. 2023 )) / Shares Outstanding (EOP) (A: May. 2023 )
=(33.0927 - 33.0927) / 33.0927
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.